Last reviewed · How we verify
NCT03114254: JAVA-P
A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis
Phase 2 trial testing Cabazitaxel in Penile Neoplasm in 17 participants. Completed in 16 November 2016.
16 November 2016
Quick facts
| Lead sponsor | University Hospitals Bristol and Weston NHS Foundation Trust |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 17 |
| Start date | 5 December 2014 |
| Primary completion | 16 November 2016 |
| Estimated completion | 16 November 2016 |
| Sites | 2 locations across United Kingdom |
Drugs / interventions tested
- Cabazitaxel (cabazitaxel) — full drug profile →
Conditions studied
- Penile Neoplasm — all drugs for Penile Neoplasm →
Sponsor
University Hospitals Bristol and Weston NHS Foundation Trust
Who can join
18 and older, male only, with Penile Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An evaluation of the activity of cabazitaxel chemotherapy in relapsed cancer of the penis. Safety and tolerability will be monitored and survival will be assessed. It is hypothesised that cabazitaxel is useful in increasing progression free survival in relapsed penile cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03114254
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cabazitaxel
Trials testing the same drug.
- NCT07213674 — A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic · Phase 3 · recruiting
- NCT06632977 — Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial · Phase 2 · recruiting
- NCT06691984 — Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressiv · Phase 3 · recruiting
- NCT06353386 — Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Particip · Phase 1, PHASE2 · recruiting
- NCT06085729 — Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Var · Phase 1, PHASE2 · recruiting
Other University Hospitals Bristol and Weston NHS Foundation Trust trials
Trials by the same sponsor.
- NCT05867576 — Acceptance and Commitment Therapy in Tuberous Sclerosis Complex · NA · unknown
- NCT05373875 — Comparison of Huntleigh Dopplex DMX Digital Doppler Arterial Waveform With the Gold Standard of Ultrasound Duplex Arteri · completed
- NCT03156452 — Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03114254 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospitals Bristol and Weston NHS Foundation Trust
- Last refreshed: 18 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03114254.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing